Fragment-Based Optimization of Dihydropyrazino-Benzimidazolones as Metabotropic Glutamate Receptor-2 Positive Allosteric Modulators against Migraine-Reference-Cited by-同舟云学术

Fragment-Based Optimization of Dihydropyrazino-Benzimidazolones as Metabotropic Glutamate Receptor-2 Positive Allosteric Modulators against Migraine

Published:2021-06-03 Issue:12 Volume:64 Page:8607-8620
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Szabó György¹^ORCID,Erdélyi Péter¹,Kolok Sándor¹,Vastag Mónika¹,Halász Attila S.¹,Kis-Varga Istvánné¹,Lévay György I.¹,Béni Zoltán¹,Kóti János¹,Greiner István¹^ORCID,Keserű György M.²^ORCID

Affiliation:

1. Gedeon Richter Plc., 19-21 Gyömrői út, Budapest 1103, Hungary

2. Medicinal Chemistry Research Group, Research Centre for Natural Sciences, 2 Magyar tudósok körútja, Budapest 1117, Hungary

Funder

Nemzeti Kutat??si Fejleszt??si ??s Innov??ci??s Hivatal

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00563

Reference29 articles.

1. Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats

2. Preclinical Pharmacology of mGlu2 / 3 Receptor Agonists: Novel Agents for Schizophrenia?

3. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

4. A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

5. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fragment-to-Lead Medicinal Chemistry Publications in 2021;Journal of Medicinal Chemistry;2023-01-09